Oruka Therapeutics' (ORKA) Buy Rating Reaffirmed at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright's target price suggests a potential upside of 121.57% from the stock's current price.

ORKA has been the subject of a number of other research reports. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $49.00 target price for the company. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a "buy" rating and a $40.00 price objective on the stock. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Leerink Partners began coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an "outperform" rating and a $44.00 target price for the company. Finally, TD Cowen started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a "buy" rating on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $43.17.

Oruka Therapeutics Stock Down 2.2 %

NASDAQ:ORKA traded down $0.45 during mid-day trading on Friday, hitting $20.31. The stock had a trading volume of 2,542,065 shares, compared to its average volume of 92,164. Oruka Therapeutics has a twelve month low of $18.20 and a twelve month high of $53.88. The company has a market capitalization of $710.83 million, a P/E ratio of -3.24 and a beta of 0.78. The firm's 50-day simple moving average is $24.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $343,000. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics in the third quarter valued at $1,037,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the third quarter valued at $2,013,000. Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $5,840,000. Finally, Redmile Group LLC purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $10,091,000. Institutional investors and hedge funds own 56.44% of the company's stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.